Aptevo Therapeutics
APVO
trading on NASDAQ
since 2016
0
(Δ 0%)
+$0.00 since open
Aptevo Therapeutics is a biotechnology company dedicated to developing innovative treatments for diseases such as cancer and blood disorders, with its lead product being pegilodecakin (LYS), an enzyme that enhances chemotherapy effectiveness in treating solid tumors.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $6.16 | $13.11 | $4.80 | $3.14M | 124.47M |
| eps | p/e | p/s |
operating margin |
profit margin |
yield |
| -$4.39 | n/a | n/a | -Inf% | -Inf% | 0% |